JP2024524213A - 治療化合物 - Google Patents

治療化合物 Download PDF

Info

Publication number
JP2024524213A
JP2024524213A JP2023578915A JP2023578915A JP2024524213A JP 2024524213 A JP2024524213 A JP 2024524213A JP 2023578915 A JP2023578915 A JP 2023578915A JP 2023578915 A JP2023578915 A JP 2023578915A JP 2024524213 A JP2024524213 A JP 2024524213A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
compound
heteroaryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524213A5 (enExample
Inventor
アジット ケー． パルヒ，
イー ユアン，
ヨンゼン ザン，
ヘスス ロサド，
プラティク ダッタ，
Original Assignee
タクシス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タクシス ファーマシューティカルズ， インコーポレイテッド filed Critical タクシス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024524213A publication Critical patent/JP2024524213A/ja
Publication of JP2024524213A5 publication Critical patent/JP2024524213A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023578915A 2021-06-22 2022-06-21 治療化合物 Pending JP2024524213A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213519P 2021-06-22 2021-06-22
US63/213,519 2021-06-22
PCT/US2022/034374 WO2022271723A1 (en) 2021-06-22 2022-06-21 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2024524213A true JP2024524213A (ja) 2024-07-05
JP2024524213A5 JP2024524213A5 (enExample) 2025-06-26

Family

ID=84544904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578915A Pending JP2024524213A (ja) 2021-06-22 2022-06-21 治療化合物

Country Status (10)

Country Link
US (1) US20240317749A1 (enExample)
EP (1) EP4359416A4 (enExample)
JP (1) JP2024524213A (enExample)
KR (1) KR20240067229A (enExample)
CN (1) CN118251394A (enExample)
AU (1) AU2022297426A1 (enExample)
CA (1) CA3225427A1 (enExample)
IL (1) IL309569A (enExample)
MX (1) MX2024000022A (enExample)
WO (1) WO2022271723A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117815240A (zh) * 2023-12-11 2024-04-05 兰州大学 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502851A (ja) * 2003-05-22 2007-02-15 ファルマシア・イタリア・エス・ピー・エー ピラゾロ−キナゾリン誘導体、その製造方法、およびキナーゼ阻害剤としてのその使用
JP2014503531A (ja) * 2010-12-17 2014-02-13 ナーヴィアノ メディカル サイエンシズ エス．アール．エル． キナーゼ阻害剤としての置換ピラゾロ−キナゾリン誘導体
US20190201401A1 (en) * 2017-08-01 2019-07-04 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
JP2020513034A (ja) * 2017-04-01 2020-04-30 晟科薬業（江蘇）有限公司Ｓｈｅｎｇｋｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｊｉａｎｇｓｕ） Ｌｔｄ． プロテインキナーゼ阻害剤としての１ｈ−イミダゾ［４，５−ｈ］キナゾリン系化合物
WO2020168017A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
JP2020530491A (ja) * 2017-08-11 2020-10-22 晟科薬業（江蘇）有限公司Ｓｈｅｎｇｋｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｊｉａｎｇｓｕ） Ｌｔｄ． プロテインキナーゼ阻害剤としての１ｈ−ピラゾロ［４，３−ｈ］キナゾリン系化合物
WO2022040596A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022042676A1 (en) * 2020-08-27 2022-03-03 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502851A (ja) * 2003-05-22 2007-02-15 ファルマシア・イタリア・エス・ピー・エー ピラゾロ−キナゾリン誘導体、その製造方法、およびキナーゼ阻害剤としてのその使用
JP2014503531A (ja) * 2010-12-17 2014-02-13 ナーヴィアノ メディカル サイエンシズ エス．アール．エル． キナーゼ阻害剤としての置換ピラゾロ−キナゾリン誘導体
JP2020513034A (ja) * 2017-04-01 2020-04-30 晟科薬業（江蘇）有限公司Ｓｈｅｎｇｋｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｊｉａｎｇｓｕ） Ｌｔｄ． プロテインキナーゼ阻害剤としての１ｈ−イミダゾ［４，５−ｈ］キナゾリン系化合物
US20190201401A1 (en) * 2017-08-01 2019-07-04 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
JP2020530491A (ja) * 2017-08-11 2020-10-22 晟科薬業（江蘇）有限公司Ｓｈｅｎｇｋｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｊｉａｎｇｓｕ） Ｌｔｄ． プロテインキナーゼ阻害剤としての１ｈ−ピラゾロ［４，３−ｈ］キナゾリン系化合物
WO2020168017A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2022040596A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022042676A1 (en) * 2020-08-27 2022-03-03 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAIGE ET AL.: "DNA structures: yDNA: A new geometry for size-expanded base pairs", ANGEWANDTE CHEMIE, vol. 43, JPN6026006868, pages 5834 - 5836, ISSN: 0005800124 *

Also Published As

Publication number Publication date
WO2022271723A1 (en) 2022-12-29
EP4359416A1 (en) 2024-05-01
AU2022297426A1 (en) 2024-02-01
MX2024000022A (es) 2024-03-15
US20240317749A1 (en) 2024-09-26
CA3225427A1 (en) 2022-12-29
IL309569A (en) 2024-02-01
CN118251394A (zh) 2024-06-25
KR20240067229A (ko) 2024-05-16
EP4359416A4 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
US11845742B2 (en) Therapeutic compounds and methods to treat infection
US9926261B2 (en) Bacterial efflux pump inhibitors
JP7281822B2 (ja) 細菌の排出ポンプ阻害剤
US9950993B2 (en) Bacterial efflux pump inhibitors
US11458121B2 (en) Therapeutic compounds and methods to treat infection
JP2656101B2 (ja) 新規ジアゾール
US8575221B2 (en) Derivatives of dimethylcurcumin
KR20180022833A (ko) 항균성 화합물
DK160276B (da) 7-(3-aminosubstitueret-1-pyrrolidinyl)-1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylsyrederivater, salte eller hydrater deraf
US11180459B2 (en) Bacterial efflux pump inhibitors
WO2018165614A1 (en) Bacterial efflux pump inhibitors
IL269210B2 (en) Indole derivatives as efflux pump inhibitors
US20190031624A1 (en) Therapeutic compounds and methods to treat infection
EP2455381A1 (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
HU194866B (en) Process for producing 7-/3-aryl-1-piperazinyl/- and 7-/3-cyclohexyl-1-piperazinyl/-3-quinoline-carboxylic acids and pharmaceutical compositions containing them as active agents
WO2017147333A1 (en) Bacterial efflux pump inhibitors
WO2017147335A1 (en) Bacterial efflux pump inhibitors
JPH0653741B2 (ja) ６，７―二置換された１―シクロプロピル―１，４―ジヒドロ―４―オキソ―１，８―ナフチリジン―３―カルボン酸類
CN104981469B (zh) 抗微生物剂
JPH01104014A (ja) ４−オキソ−４ｈ−キノリジン−３−カルボン酸及びその誘導体
EP4359416A1 (en) Therapeutic compounds
CA2004693A1 (en) Antibacterial quinolone compounds
JPS62490A (ja) １，８−架橋した４−キノロン−３−カルボン酸類
US4962112A (en) 7-(2-methyl-4-aminopyrrolidinyl)naphthryidine and quinoline compounds
JPS6246523B2 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260519